Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Translation - UK version of Swedish press release - published 08.00 AM. today - SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

SynAct Pharma AB ("SynAct") today announced that the company investigates the possibility of developing its clinical anti-inflammatory lead candidate drug AP1189 as an additional therapy in hospitalized patients with COVID-19 infection, to prevent Acute Respiratory Distress Syndrome (ARDS). ARDS is the most common cause of death among patients with COVID-19 (SARS-CoV-2).SynAct intends to explore the possibility of applying AP1189 to clinics through potential funding from government institutions and commercial partners operating in the COVID-19 area. This is exploratory and conditional on

Sectra wins enterprise imaging contract at the MetroHealth System in the U.S.

Linköping, Sweden and Shelton, CT – March 31, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will install the radiology and breast imaging modules of its enterprise imaging solution at MetroHealth. The Sectra solution, integrated with Epic Radiant, will allow workflow optimization for all radiologists and radiology residents within the health system.MetroHealth provides care to residents of Northeastern Ohio, of which 75% of visits come from the uninsured and those covered by Medicare and Medicaid. They are the only verified

Beijer Ref advances the Annual General Meeting

Due to recent developments in the spread of the corona virus, Beijer Ref’s board of directors has decided to move the Annual General Meeting to a later date. Through this, the company helps to reduce the risk of further spread of infection in society. The Annual General Meeting was previously scheduled to be held on April 16, 2020. ” The great uncertainty surrounding the spread of the corona virus and its effects makes the Board of Directors believe that the best thing to do in the situation is to postpone the Annual General Meeting. We will now focus on helping our customers at a very

New AI-powered virtual assistant for professional use

We’re used to chatting with computers nowadays. We talk to Siri and Alexa, for example, in our homes and our cars. But for many companies, services of this kind aren’t an option due to security classified data. Semcon has used the very latest in artificial intelligence to develop a revolutionary virtual assistant for professional use: SIA (Semcon Intelligent Assistant).The more advanced the technology surrounding us, the more complex it is to maintain. Moreover, the data volumes that companies have to manage are becoming increasingly substantial. Another challenge is that data can be stored

New number of shares and votes in Cantargia

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see the company’s press releases on 19 February and 16 March 2020). Through the share issue, the number of shares and votes in Cantargia increased by 10,920,658. Today, on the last trading day of the month, there are in total 91,005,489 shares and votes in Cantargia. For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This is information that Cantargia AB (publ)

Elos Medtech - Annual Report and Sustainability Report 2019 is published

Elos Medtech AB’s Swedish language Annual Report for 2019, as well as the English language Sustainability Report for 2019, have today been published on our website, www.elosmedtech.com The Annual Report for 2019 can be found under IR and Financial reports. The Sustainability Report for 2019 is published under About Us and Sustainability. The English version of Elos Medtech Annual Report 2019 will be available at the website www.elosmedtech.com in late April.   About Elos Medtech Elos Medtech is a leading development and production partner for medical devices and components, with

DDM provides update on strategic investment

DDM Holding AG (First North: DDM) announces that it has exercised the call option to acquire an additional 10.1% stake in Addiko Bank AG, an Austrian bank with operations in DDM’s core markets in the Balkans, from AI Lake (Luxembourg) S.à r.l. The commercial terms of the call option have been adjusted since the initial investment. The transaction is subject to regulatory approval.   At 31 December 2019 the bank had EUR 6.1 billion of total assets, including a net loan book of EUR 3.9 billion mostly towards consumers and SME customers, with an NPE ratio of 3.9%. DDM is a highly

DDM Debt provides update on strategic investment

DDM Debt AB (Nasdaq Stockholm: DDM2) announces that it has exercised the call option to acquire an additional 10.1% stake in Addiko Bank AG, an Austrian bank with operations in DDM’s core markets in the Balkans, from AI Lake (Luxembourg) S.à r.l. The commercial terms of the call option have been adjusted since the initial investment. The transaction is subject to regulatory approval.   At 31 December 2019 the bank had EUR 6.1 billion of total assets, including a net loan book of EUR 3.9 billion mostly towards consumers and SME customers, with an NPE ratio of 3.9%. DDM is a highly

Positive preliminary results from first comparative study with the Episealer® Knee implant

Episurf Medical (Nasdaq: EPIS B) today announces promising results from the study with the title “X-ray fluoroscopic analysis of knee joint kinematic in open and closed chain activities in patients with Episealer Knee implants” performed at Charité University Hospital, Berlin. Preliminary results show good patient satisfaction and good knee function. The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the femoral side of the knee joint. The Episealer® Knee implant is fully tailored to fit each patient’s unique curvature of the joint

Publication of Karnov Group’s Annual Report of 2019

At a Board meeting of Karnov Group AB (publ), the Annual Report of Karnov Group for the fiscal year 2019 has been presented and approved. The Annual Report also includes the Corporate Governance Report and Sustainability Report of 2019.The Annual Report is available on https://www.karnovgroup.com/en/financial-reports-and-presentations/. The Annual Report is also available in the company’s main office and will be sent to shareholders requesting it. The Board of Directors proposes the annual general meeting to approve a dividend of SEK 0.45 per share. The Annual Report does not contain any

Update on the coronavirus impact

As the impact on society of the coronavirus is by no means clear, Volati is issuing a general update. As of 30 March 2020, it is Volati’s assessment that overall disruptions to the business have had a limited effect on the Group’s earnings and cash flow. Given the exceptional developments in the world, it is Volati’s assessment that the risk of future negative effects has increased but the extent of the potential impact on the Company cannot be predicted. In readiness for any future negative deviations, Volati has spent about three weeks working systematically on measures to protect

Press Release: Awarded grant to develop a novel electrolyser stack to enable lower cost hydrogen generation

(Oslo, 31 March, 2020) Proton Energy Systems, Inc. (dba “Nel Hydrogen US”), a wholly owned subsidiary of Nel ASA (Nel, OSE:NEL), has been awarded a $1.85 million grant by the Department of Energy (DOE) for development of a novel electrolyser cell stack approach to enable higher efficiency, low cost hydrogen generation.   “We are very excited to receive this award from the DOE. Success of this project will not only demonstrate a cost-effective pathway for hydrogen energy storage, but it will also help further improve our electrolysers in general, enabling lower cost hydrogen generation

Partial redemption of Golden Heights Aktiebolag (Publ) Notes ISIN: SE0010599498 (the "Notes")

The partial redemption of the Notes according to Clause 10.4.1 of the Terms and Conditions for the Notes, which is due for payment on 31 March 2020, will, because of technical and administrative error, be paid, together with default interest, to each Noteholder on 2 April 2020. To be eligible for payment, you must be a noteholder on 24 March 2020. The nominal amount of each Note will, after the partial redemption, be reduced with 5%. The nominal amount of each Note will after the partial redemption on 2 April 2020 amount to SEK 1,187,500. The reduced nominal amount per Note will, however,

Director/PDMR Shareholding

31 March 2020 07:00 BST   Transactions by Persons Discharging Managerial ResponsibilitiesDisclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announced that, on 27 March 2020, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Performance Share Plan (AZPSP). The AZPSP award was granted on 27 March 2015 and was subject to a three-year performance period followed by a two-year holding period before vesting.

Africa Oil Announces Share Capital Update

VANCOUVER, March 31, 2020 /CNW /- (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act. As a result of the issuance of 735,387 common shares in connection with the settlement of restricted share units and performance share units under the Company’s long-term incentive plan during the month, the number of issued and outstanding shares of the Company has increased to 471,949,806 common shares with voting rights as at March 31,

Nel ASA: Commencement of Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. (Oslo, 31 March 2020) Reference is made to the stock exchange announcement by Nel ASA ("Nel" or the "Company") on 30 March 2020, regarding the approval of a prospectus relating to a subsequent offering of up to 13,350,000 new shares (the "Subsequent Offering") to be carried out by the Company following the completion of a private placement with gross

NOTICE OF ANNUAL GENERAL MEETING IN RABBALSHEDE KRAFT AB (PUBL)

Rabbalshede Kraft AB (publ), Reg. No.: 556681-4652, hereby gives notice to shareholders to attend the Annual General Meeting on 28 April 2020 at 1:30 p.m. at MAQS Advokatbyrå, Östra Hamngatan 24 in Gothenburg, Sweden. Registration for the Annual General Meeting starts at 1:00 p.m. Due to Covid-19, the company’s intention is to let shareholders be given the opportunity to follow the AGM by video link but such shareholders will not be included in the voting register. The decision to follow the proceedings at the AGM by video link will only be valid where supported by the majority of the

Publication of H & M Hennes & Mauritz AB’s Annual Report 2019

H & M Hennes & Mauritz AB’s Annual Report for the financial year 2019 is available starting today on the company’s website, hmgroup.com. The annual report will be sent out by post to shareholders that have so requested and will also be available at the company’s head office.  Contact persons:Nils Vinge, Head of Investor RelationsTelephone: +468-796 5250 Kristina Stenvinkel, Communications DirectorTelephone: +468-796 3908 Press pictures and background information for editorial use can be downloaded from hmgroup.com/media.This information is information that H & M Hennes &

Revenio Group Corporation: Jouni Toijala appointed as the CEO of Revenio Group Corporation

Revenio Group Corporation, Stock Exchange Release, March 31, 2020, at 9.00 am EETJOUNI TOIJALA APPOINTED AS THE CEO OF REVENIO GROUP CORPORATION B.Sc., MBA Jouni Toijala, (b. 1968) has been appointed as the CEO of Revenio Group Corporation and its’ subsidiaries as of September 30[th], 2020 at the latest. Timo Hildén, the long-term CEO of Revenio and Icare Finland, is committed to supporting Jouni when he takes on his role to ensure a smooth transition. Jouni Toijala has been the CEO of Innokas Medical Oy, a provider of health technology design and manufacturing services to leading

Skanska builds multi-family buildings for Stena Fastigheter in Gothenburg, Sweden, for about SEK 550 M

Skanska has signed a contract with Stena Fastigheter AB to build multi-family buildings in Ekebäckshöjd in Gothenburg, Sweden. The contract is worth about SEK 550 M, which will be included in the order bookings for Sweden for the first quarter 2020.In total, 361 apartments will be built, both condominiums and rental apartments, and the buildings will also house a preschool and retail premises. The project covers 38,000 square meters and the buildings will be between six and eleven floors high. Ekebäckshöjd is located in close proximity to good communications and service. Relationship

Trading Update on the Basis of COVID-19 and Changed Market Conditions

EG7 is following the global development of COVID-19 and its potential effect on the gaming industry and EG7’s business. EG7 has taken several measures to follow regulations and guidelines from authorities in the countries where the group operates, with main focus being to protect the well-being and safety of our employees and other parties. In this trading update, EG7 presents a trading update for January and February 2020 and management’s view of the COVID-19 effect on its three business units for the coming quarters.   Trading update for the period 1 January – 29 February 2020[(1)

Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection

Gothenburg, March 31, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the submission of a Letter of Intent to file a clinical trial application (CTA) to the UK regulatory agency (MHRA[1]) for a phase II study with its proprietary compound C21 in patients with COVID-19, SARS CoV-2 infection.Together with the Letter of Intent, Vicore Pharma has submitted the first regulatory documents for initial review in a rolling submission, as recently agreed with the MHRA. The formal application will be submitted as soon

Peab builds student housing in Björkhagen

Peab has been commissioned to build 166 energy efficient student apartments in Björkhagen, south of Stockholm. The customer is Stiftelsen Stockholms studentbostäder, SSSB and the contract is worth SEK 152 million.Peab will build 166 new student apartments in Björkhagen divided into three sections consisting of two low-rise apartment buildings and one high-rise. In order to reduce both costs and construction time the buildings’ framework will be built with a prefabricated concrete consisting of so-called flat concrete slabs and external solid walls with a ready-made brick façade. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top